Apixaban reduces the risk of major and clinically relevant non-major bleeding compared to warfarin in patients with end stage renal disease; a systematic review and meta-analysis of ten studies
Optimal anticoagulation in patients with end-stage renal disease ESRD is a matter of debate since these patients are not included in randomized controlled trials (RCTs). Evolving data are in favor of apixaban compared to warfarin. (Source: Thrombosis Research)
Source: Thrombosis Research - September 20, 2023 Category: Hematology Authors: Konstantinos Zagoridis, Lazaros Karatisidis, Theodoros Mprotsis, Aikaterini Pentidou, Zoi Bezirgianidou, Christina Misidou, Emmanouil Spanoudakis Tags: Full Length Article Source Type: research
Performance of the 4-Level Pulmonary Embolism Clinical Probability Score (4PEPS) in the diagnostic management of pulmonary embolism: An external validation study
The recently published 4-level Pulmonary Embolism Clinical Probability Score (4PEPS) integrates different aspects from currently available diagnostic strategies to further reduce imaging testing in patients with clinically suspected pulmonary embolism (PE). (Source: Thrombosis Research)
Source: Thrombosis Research - September 20, 2023 Category: Hematology Authors: Milou A.M. Stals, Ludo F.M. Beenen, Michiel Coppens, Laura M. Faber, Herman M.A. Hofstee, Marcel M.C. Hovens, Menno V. Huisman, Tom van der Hulle, Karin A.H. Kaasjager, Marieke J.H.A. Kruip, Albert T.A. Mairuhu, Saskia Middeldorp, Marije ten Wolde, Freder Tags: Full Length Article Source Type: research
The CORONA-VTE network registry: Revisiting the realities while encouraging enthusiasm
We appreciate the interest by Theodorou and colleagues in the CORONA-VTE Network registry. While we agree that the registry is well-positioned to provide answers for several understudied aspects of COVID-19-associated thrombosis [1], we also want to make sure that the expectations from the registry are set in a reasonable way. (Source: Thrombosis Research)
Source: Thrombosis Research - September 18, 2023 Category: Hematology Authors: Behnood Bikdeli, Gregory Piazza, CORONA-VTE-Network Investigators Tags: Letter to the Editors-in-Chief Source Type: research
Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Rationale and methodology of the CORONA-VTE-Network study
Bikdeli B. et al. [1] recently introduced the CORONA-VTE-Network study, an intended analysis of the adverse cardiovascular and thrombotic events in patients with COVID-19, distilling data from initial CORONA-VTE registry [2]. This large registry of 10,000 patients derived from prestigious healthcare institutions across the United States, is expected to shed light on key issues related to serious adverse outcomes of COVID-19 disease. As declared by these authors, investigators will systematically review and record detailed clinical and laboratory data from available patient electronic database systems to examine the rates o...
Source: Thrombosis Research - September 16, 2023 Category: Hematology Authors: Daphne J. Theodorou, Stavroula J. Theodorou, Dimitrios Rizos Tags: Letter to the Editors-in-Chief Source Type: research
Targeted delivery of miR125a-5p and human Factor VIII attenuates molecular mediators of hemophilic arthropathy
Hemophilic arthropathy (HA) due to repeated bleeding into the joint cavity is a major cause of morbidity in patients with hemophilia. The molecular mechanisms contributing to this condition are not well characterized. MicroRNAs (miRs) are known to modulate the phenotype of multiple joint diseases such as osteoarthritis (OA) and rheumatoid arthritis (RA). Since miR125a is known to modulate disease progression in OA and RA, we performed a targeted screen of miR125a-5p and its target genes in a murine model of chronic HA. (Source: Thrombosis Research)
Source: Thrombosis Research - September 15, 2023 Category: Hematology Authors: Mohankumar B. Senthilkumar, Pratiksha Sarangi, Sonal Amit, Senthilnathan Senguttuvan, Narendra Kumar, Giridhara R. Jayandharan Source Type: research
Hemostatic considerations for gender affirming care
Gender dysphoria or gender incongruence is defined as “persons that are not satisfied with their designated gender” [1]. The awareness and evidence-based treatment options available to this population have grown immensely over the last two decades. Protocols now include an Endocrine Society Clinical Practice Guideline [1] as well as the World Profe ssional Association of Transgender Health Standards of Care (WPATH SOC) [2]. Hematologic manifestations, most notably thrombosis, are one of the most recognized adverse reactions to the hormones used for gender-affirming care. (Source: Thrombosis Research)
Source: Thrombosis Research - September 13, 2023 Category: Hematology Authors: Kathleen Garland, Eric Mullins, Rachel S. Bercovitz, Vilmarie Rodriguez, Jean Connors, Nancy Sokkary Tags: Review Article Source Type: research
Platelets provide robustness of spatial blood coagulation to the variation of initial conditions
Activated platelets provide phospholipid surface and secrete coagulation factors, enhancing blood clotting. We investigated the role of platelets in the regulation of blood coagulation spatial dynamics. We activated blood clotting with tissue factor-bearing (TF) surface in platelet-rich plasma (PRP) or platelet-free plasma (PFP). When blood coagulation was initiated by high TF density, clot growth rate (V) in PRP (2 × 105/μL platelets) was only 15 % greater than in PFP. Spatial distribution of thrombin in PRP had a peak-like shape in the area of the fibrin clot edge, while in PFP thrombin was distributed in the sh...
Source: Thrombosis Research - September 13, 2023 Category: Hematology Authors: Anna N. Balandina, Ekaterina M. Koltsova, Alexey M. Shibeko, Anna D. Kuprash, Valentina A. Budkova, Irina A. Demina, Anastasiya A. Ignatova, Olga A. Fadeeva, Ramya Vijay, Sukesh C. Nair, Alok Srivastava, Qiang Shi, Fazoil I. Ataullakhanov, Mikhail A. Pant Source Type: research
Breaking down tumor thrombus: Current strategies for medical management
Tumor thrombus, the intravascular extension of tumor into adjacent blood vessels, is frequently encountered in patients with renal cell carcinoma and hepatocellular carcinoma, and often involves the abdominal vasculature including the renal vein, portal vein, and the inferior vena cava. While a bland thrombus is composed of platelets and fibrin, in contrast, a tumor thrombus refers to an organized collection of tumor cells. Though oftentimes detected incidentally on imaging, tumor thrombus may have significant clinical implications and can be challenging to differentiate from bland thrombus. (Source: Thrombosis Research)
Source: Thrombosis Research - September 12, 2023 Category: Hematology Authors: Harsha Tathireddy, Douglas Rice, Kylee Martens, Sudeep Shivakumar, Joseph Shatzel Tags: Review Article Source Type: research
Safety and efficacy of oral anticoagulants in extreme weights
The 2021 International Society on Thrombosis and Haemostasis' (ISTH) recommends standard doses of apixaban and rivaroxaban regardless of high body mass index (BMI) and weight, but had not compare DOACs head-to-head in obesity or address underweight patients. (Source: Thrombosis Research)
Source: Thrombosis Research - September 11, 2023 Category: Hematology Authors: J. Chin-Hon, L. Davenport, J. Huang, M. Akerman, A. Hindenburg Tags: Full Length Article Source Type: research
In vitro effects of Gla-domainless factor Xa analog on procoagulant and fibrinolytic pathways in apixaban-treated plasma and whole blood
Andexanet alfa is a Gla-domainless FXa (GDXa) analog used as an antidote to FXa inhibitors. Despite its clinical use, laboratory monitoring for anti-Xa reversal and the effect of andexanet on fibrinolysis has not been explored. We used a GDXa with a serine-to-alanine mutation at position 195 (chymotrypsin numbering) to model the interaction between andexanet and apixaban. (Source: Thrombosis Research)
Source: Thrombosis Research - September 8, 2023 Category: Hematology Authors: Rui Terada, Penny M. Johnson, Amir Butt, Yuko Mishima, Kenneth E. Stewart, Jerold H. Levy, Kenichi A. Tanaka Tags: Full Length Article Source Type: research
Plasma protein signatures for high on-treatment platelet reactivity to aspirin and clopidogrel in peripheral artery disease
A significant proportion of patients with peripheral artery disease (PAD) displays a poor response to aspirin and/or the platelet P2Y12 receptor antagonist clopidogrel. This phenomenon is reflected by high on-treatment platelet reactivity (HTPR) in platelet function assays in vitro and is associated with an increased risk of adverse cardiovascular events. (Source: Thrombosis Research)
Source: Thrombosis Research - September 1, 2023 Category: Hematology Authors: G. Baidildinova, A. Pallares Robles, V. ten Cate, B.M.M. Kremers, S. Heitmeier, H. ten Cate, B.M.E. Mees, H.M.H. Spronk, P.S. Wild, A.J. ten Cate-Hoek, K. Jurk Source Type: research
Editorial Board
(Source: Thrombosis Research)
Source: Thrombosis Research - August 31, 2023 Category: Hematology Source Type: research
Transcriptome analysis suggests a central role for complement and C5aR1 in neutrophil activation in APS
Antiphospholipid syndrome (APS) is characterized by thrombosis and/or recurrent pregnancy loss in the presence of persistently positive antiphospholipid antibodies (aPL). APS, particularly the most severe variant, catastrophic APS (CAPS) is associated with complement activation and a high incidence of complement regulatory gene mutations [1]; moreover, complement inhibition has been effective in preventing recurrent thrombosis in some patients with APS [2]. The pathogenesis of thrombosis in APS is not well understood, and likely multifactorial [3]. (Source: Thrombosis Research)
Source: Thrombosis Research - August 30, 2023 Category: Hematology Authors: Ahmed Alarabi, Anne Hubben, John Barnard, Jason S. Knight, Keith R. McCrae Tags: Letter to the Editors-in-Chief Source Type: research
Thromboembolic and bleeding complications during interruptions and after discontinuation of anticoagulant treatment in patients with atrial fibrillation and active cancer: A daily practice evaluation
Cancer provides challenges to the continuity of anticoagulant treatment in patients with atrial fibrillation (AF), e.g. through cancer-related surgery or complications. We aimed to provide data on the incidence and reasons for interrupting and discontinuing anticoagulant treatment in AF patients with cancer and to assess its contribution to the risk of thromboembolism (TE) and major bleeding (MB). (Source: Thrombosis Research)
Source: Thrombosis Research - August 29, 2023 Category: Hematology Authors: Gordon Chu, Jaap Seelig, Suzanne C. Cannegieter, Hans Gelderblom, Marcel M.C. Hovens, Menno V. Huisman, Tom van der Hulle, Serge A. Trines, Andr é J. Vlot, Henri H. Versteeg, Martin Hemels, Frederikus A. Klok Tags: Full Length Article Source Type: research
Recent advances of oxidative stress in thromboangiitis obliterans: Biomolecular mechanisms, biomarkers, sources and clinical applications
Oxidative stress (OS) has been identified as a key factor in the development of Thromboangiitis Obliterans (TAO). The detection of OS levels in clinical and scientific research practice is mainly based on the measurement of oxidative stress such as reactive oxygen species (ROS), reactive nitrogen species (RNS) and lipid peroxides. These markers are typically assessed through a combination of physical and chemical methods. Smoking is known to the state of OS in TAO, and OS levels are significantly increased in smokers due to inadequate antioxidant protection, which leads to the expression of apoptotic proteins and subsequen...
Source: Thrombosis Research - August 24, 2023 Category: Hematology Authors: Qi Chen, Jing Chen, Jiahua Li, Yuanyuan Cheng, Rong Zhang, Zhongqiu Liu Tags: Review Article Source Type: research
